If severe respiratory distress, facial or oral edema, and/or hypoperfusion
OR
If patient has a history of anaphylaxis and has an exposure to an allergen developing respiratory distress and/or hypoperfusion and/or rash:
Epinephrine (1 mg/mL) 0.3 mg IM if ≥30 kg‡¹
Epinephrine (1 mg/mL) 0.15 mg IM if <30 kg‡²,³
If the patient does not improve within 5 minutes, may repeat once
EMT and up
If wheezing, Albuterol⁴ 2.5 mg via nebulizer; may repeat to a total of three doses
May be combined with Ipratropium (Atrovent) 0.5 mg in 2.5 mL (unit dose) ‡
Medical control
Epinephrine for indications other than those above
Additional Albuterol
Key points
1. Epinephrine 0.3 mg may be administered via Adult Autoinjector (CFR or higher) or Syringe Epi Kit (EMT or higher)
2. Epinephrine 0.15 mg may be administered via Pediatric Autoinjector (CFR or higher) or Syringe Epi Kit (EMT or higher)
3. Infant Auto Injector (0.1 mg IM) may be substituted for pediatric patients <15 kg, if available (CFR or higher)
4. A combination unit dose (such as a DuoNeb®) may be substituted for Albuterol 2.5 mg in 3 mL (unit dose) & Ipratropium (Atrovent) 0.5 mg in 2.5 mL (unit dose) mixed together
If Epinephrine is administered by crew or patient self-administered Epinephrine, regional procedure may require consulting medical control prior to honoring a request for refusal of medical care
Though a previous history of anaphylaxis is an important indicator for treatment, providers should be aware that anaphylaxis may develop in patients with no prior history
Anaphylaxis may present with shock associated only with GI symptoms. In the setting of a known exposure to an allergen associated with shock, where the presenting symptom is nausea, vomiting, abdominal pain, and/or diarrhea, consider anaphylaxis in consult with medical control.